anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method, device and system for transceiving clinical trial related information includes a client device and a server that communicate. An application of the client device has a client application of a clinical trial service whose server application is running on the server. A coordinator user profile with credentials and a user profile with credentials are maintained. The coordinator credentials are determined to be be authorized. The coordinator user obtains access to the application. Coordinator input data triggers user change for the client device. A request to the server application indicating the triggered user change is sent. Credentials are received from the server application and associated with the user profile. The coordinator user is logged out by disconnecting coordinator level access to the proprietary application and resetting the coordinator credentials and session data within the client device. The credentials are stored for automatic first logging in of the user.
ABSTRACT         A DNA sequence comprising the sugar beet chitinase 4 DNA sequence shown in Sequence 1 or an analogue or subsequence thereof is disclosed. The polypeptide encoded by the DNA sequence, also termed the sugar beet chitanase 4 enzyme, has a high antifungal activity due to a hitherto unreported bifuncitoanl catalytic activity (i.e. a chitianase and a lysozyme activity) which makes the enzyme highly effective in inhibiting the growth of chitin-containing fungi. An even improved antifungal effect is obtained when the sugar beet sugar beet chitinase 4 enzyme is used in combination with other pathogenesis related proteins, especially in combination with a second different chitinase and a .beta.-1,3-glucanase. A preferred use of the DNA sequence disclosed hererin, optionally in combination with DNA construction of genetically transformed plants, especially genetically transformed sugar beet plants, having an increased resistance to chitin-contiaining fungi as compared to untransformed plants.     829540ab.001/LS/JKM/A12/1991 07 29
Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
The invention belongs to the field of ethnic medicines and discloses an externally used Yao medicine composition for treating gout and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 3-30 parts of root of catclaw buttercup, 3-30 parts of trachelospermum jasminoides(Lindl.)Lam., 3-30 parts of root of clematis chinensis osbeck, 3-30 parts of barks, branches and leaves of ilex rotunda thunb., 3-30 parts of plantago major L. and 3-30 parts of herb of gynura divaricate(L.)DC. The dosage form of the composition is powder. The preparation method comprises the processes of grinding, baking and sterilizing the raw medicines, thus preparing the powder. The composition is externally applied or is used for fumigation. Clinical tests show that the medicine composition has the functions of removing toxicity for diminishing swelling, dredging the channels and activating the collaterals, removing stasis to relieve pains, as well as promoting swelling diminishing and relieving joint pain so as to achieve the aim of treating gout. The Yao medicine composition takes effect quickly, has stable curative effects and no toxic or side effect, and is a health protection medicine with preventive and therapeutic effects on gout.
Sodium Sulfacetamide 10% Wash is available in 16 fluid ounce bottles, NDC 42192-129-16.

Store at controlled room temperature, 15° - 30°C (59° - 86°F). Do not freeze.

Note: Store upright. Protect from freezing and excessive heat. The wash may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product. Occasionally, a slight yellowish discoloration may occur when an excessive amount of the wash is used and comes in contact with white fabrics. This discoloration, however, presents no problem, as it is readily removed by ordinary laundering without bleaches. 

All prescription substitutions using this product shall be made subject to state and federal statutes as applicable.  NOTE: this is not an Orange Book product and has not been subjected to FDA therapeutic equivalency or other equivalency testing. No representation is made as to generic status or bioequivalency. Each person recommending a prescription substitution using this product shall make such recommendations based on each such person’s professional opinion and knowledge, upon evaluating the active ingredients, excipients, inactive ingredients and chemical formulation information provided herein. 

MANUFACTURED FOR: Acella Pharmaceuticals, LLC   
Alpharetta, GA 30009   
1-800-541-4802   
Rev. 1010v2
PCT No. PCT/JP92/01619 Sec. 371 Date Jun. 10, 1994 Sec. 102(e) Date Jun. 10, 1994 PCT Filed Dec. 10, 1992 PCT Pub. No. WO93/12117 PCT Pub. Date Jun. 24, 1993An immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor, each containing a thienotriazolodiazepine compound wherein the 2-position of its diazepine ring is alkylated as an active ingredient, an immunosuppression method, an autoimmune disease treating method, an immunosuppression enhancing method and a cell adhesion inhibiting method, each of which comprising administering the compound, and uses of the compound for the production of an immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor.
Developmental prosopagnosia (DP) is associated with considerable perceptual heterogeneity, though the nature of this heterogeneity and whether there are discrete subgroups versus continuous deficits remains unclear. Bennetts et al. (2022) recently found that holistic versus featural processing deficits distinguished discrete DP subgroups, but their sample was relatively small (N = 37), and subgroups were defined using a single task. To characterize perceptual heterogeneity in DPs more comprehensively, we administered a broad face perception battery to a large sample of 109 DPs and 134 controls, including validated measures of face matching (Cambridge Face Perception Test - CFPT, Computerized Benton Facial Recognition Test, Same/Different Face Matching Task), holistic processing (Part-Whole Task), and feature processing (Georges Task and Part-Whole part trials). When examining face matching measures, DPs exhibited a similar distribution of performance as controls, though shifted towards impairment by an average of 1.4 SD. We next applied Bennetts (2022) hierarchical clustering approach and k-means clustering to the CFPT upright, inverted, and inversion index measures, similarly finding one group of DPs with poorer inverted face performance and another with a decreased face inversion effect (holistic processing). However, these subgroup differences failed to generalize to other measures of feature and holistic processing beyond the CFPT. We finally ran hierarchical and k-means cluster analyses on our larger battery of face matching, feature, and holistic processing measures. Results clearly showed subgroups with generally better versus worse performance across all measures, with the distinction between groups being somewhat arbitrary. Together, these findings support a continuous account of DP perceptual heterogeneity, with performance differing primarily across all aspects of face perception.
BACKGROUND: Recent studies have indicated that depression is associated with persistent postoperative pain and decreased satisfaction following foot and ankle surgery. This study aimed to evaluate the effect of perioperative duloxetine on postoperative outcomes of anterior talofibular ligament (ATFL) surgical repair for chronic ankle instability (CAI) in patients with depression. We further sought to evaluate patients' satisfaction and side effects related to duloxetine.
MATERIAL AND METHODS: Patients undergoing ATFL repair were screened for depression preoperatively with the Patient Health Questionnaire (PHQ-9). Among 249 patients who underwent arthroscopic or open surgical Brostrom repair of the ATFL, 120 patients were identified as being "possibly depressed" and were included in the study. Sixty patients were randomly assigned to the duloxetine group (one day preoperatively and for 6 weeks postoperatively), and the other sixty were randomized to the placebo group. Painkillers and opioid consumption, pain scores, and patient satisfaction were recorded at 12, 24, 48, and 72hours postoperatively and at follow-up visits 1, 3, and 6 months after surgery. Patient-reported outcome measures (PROMs) were assessed preoperatively and at 3, 6, 12 and 24 months postoperatively. Duloxetine-related side effects such as nausea/vomiting and fatigue were also recorded.
RESULTS: The patients in the duloxetine group reported a significantly longer time to rescue analgesic and reduced opioid requirements (including celecoxib, pregabalin, acetaminophen, and tramadol). The patients experienced decreased pain intensity and greater satisfaction with their pain management at 24, 48, 72h and 1 and 3 months after surgery (p<0.05). The duloxetine group also had significantly better clinical and functional outcomes at 3 and 6 months of follow-up compared to the placebo group (p<0.05). The occurrence and rate of symptoms of duloxetine side effects were not significant.
DISCUSSION: Depression is an important factor to consider and address because its presence before surgery can predict poor postoperative outcomes, including more severe postoperative pain, persistent postoperative pain, and increased consumption of painkillers and opioids.
CONCLUSION: Perioperative administration of duloxetine following ATFL repair for CAI in patients with depression increased the time to first postoperative rescue analgesic request and reduced both opioid consumption and postoperative pain. This approach also led to a high level of patient satisfaction. In addition, duloxetine improved the quality of recovery without leading to significant side effects.
LEVEL OF EVIDENCE: I; prospective randomized controlled trial.
Anderson - Fabry disease (AFD) is a rare, X - linked hereditary systemic lysosomal storage disorder which usually affects the heart. The reported incidence of AFD is between 1 in 117000 and 1 in 240000 live births. Due to a deficiency of the enzyme α - galactosidase, glycosphingo-lipids, primarily globotriaosylceramide, are stored also in endothelial and myocardial cells, leading to morphologic and functional changes. AFD-cardiomyopathy progresses with age and with the course of the disease, leading to reduced life expectancy. The investigators hypothesize, that AFD could be underdiagnosed in patients with only mild or moderate left ventricular myocardial hypertrophy. Early diagnosis of AFD may be relevant since affected patients might benefit from enzyme replacement therapy at early stage of disease. The investigators will examine 4000 consecutive patients with an echocardiographically measured interventricular septum thickness of ≥ 12mm. Urine samples will be collected and Gb3-isoforms, creatinine and α - Galactosidase activity will be measured.
BACKGROUND: Basic scientists have used preclinical animal models to explore mechanisms driving human diseases for decades, resulting in thousands of publications, each supporting causative inferences. Despite substantial advances in the mechanistic construct of disease, there has been limited translation from individual studies to advances in clinical care. An integrated approach to these individual studies has the potential to improve translational success.
METHODS: Using atherosclerosis as a test case, we extracted data from the 2 most common mouse models of atherosclerosis (ApoE [apolipoprotein E]-knockout and LDLR [low-density lipoprotein receptor]-knockout). We restricted analyses to manuscripts published in 2 well-established journals, Arteriosclerosis, Thrombosis, and Vascular Biology and Circulation, as of query in 2021. Predefined variables including experimental conditions, intervention, and outcomes were extracted from each publication to produce a preclinical atherosclerosis database.
RESULTS: Extracted data include animal sex, diet, intervention type, and distinct plaque pathologies (size, inflammation, and lipid content). Procedures are provided to standardize data extraction, attribute interventions to specific genes, and transform the database for use with available transcriptomics software. The database integrates hundreds of genes, each directly tested in vivo for causation in a murine atherosclerosis model. The database is provided to allow the research community to perform integrated analyses that reflect the global impact of decades of atherosclerosis investigation.
CONCLUSIONS: This database is provided as a resource for future interrogation of sub-data sets associated with distinct plaque pathologies, cell type, or sex. We also provide the methods and software needed to expand this data set and apply this approach to the extensive repository of peer-reviewed data utilizing preclinical models to interrogate mechanisms of diverse human diseases.
Daily passive music listening will be required for 30 minutes twice a day, at least 4 days per week. This daily listening experience will consist of non-personalized, auto-generated playlists based on popular genres. No interaction with a music therapist will occur.
Patients with acute Leukemia may have a large number of leukemic cells at the time that leukemia is evident clinically. At the time that we determine that a patient is in complete remission (CR) the patient may still have leukemic cells present in smaller quantities. One of the most important factors in the successful treatment of patients with leukemia is the ability to determine if the eradication of leukemia has been achieved. The determination of Minimal Residual Disease may be important in the determination of the therapy that a given patient will receive as determined by the level of residual disease.

WT1 gene function and expression. The WT1 gene is a candidate gene for Wilms tumor, which is thought to arise as a result from inactivation of both alleles of the WT1 gene located at chromosome 11p13. The WT1 gene has been considered a tumor suppressor gene because intragenic deletions or mutations are found in tumors, germline mutations have been found in-patients with leukemia, and mediates growth suppression of Wilms tumor cells expressing a WT1 splicing variant.
The invention discloses an application of Zfp217 gene in preparing a medicament for treating osteoporosis, and belongs to the field of biological medicine. The invention provides application of an agent for inhibiting Zfp217 gene expression in preparation of a medicament for treating osteoporosis. The agent for inhibiting Zfp217 gene expression comprises an aptamer for inhibiting Zfp217 gene expression in bone marrow mesenchymal stem cells. The first experiment proves that inhibiting the expression of Zfp217 gene can relieve bone loss caused by estrogen deficiency or mechanical stress deficiency. The invention also discloses an action part of negative regulation of osteoblast differentiation and positive regulation of adipogenesis of Zfp217, which can inhibit the expression of Zfp521 by competitively combining with ER alpha to lead mesenchymal stem cells to differentiate into adipose tissue, finally reduce bone formation and increase adipogenesis. The invention provides a new mechanism and a new therapeutic target for treating osteoporosis.
A method for managing network-based electronic commerce digital communications and associated user-health information can comprise accessing health related information for a user of an electronic payment system. The method can also comprise determining based upon the health related information, a particular health attribute of the user. The method can further comprise matching the metadata associated with an advertisement campaign indicator with the particular health attribute of the user. Additionally, the method can comprise matching information associated with an interactive object with the particular health attribute of the user. The method can comprise generating a benefit data structure that comprises a user-interaction tracking metric. Further, the method can comprise detecting a user interaction with the interactive object within the mobile wallet application. Based upon the detecting interaction, the method can comprise updating the user-interaction tracking metric.
All participants in this study fall into this non randomized single group. These participants will complete a total of 12 bodyweight training sessions over a six to eight week time period. Participants will attend one session per week at Holy Name Medical Center's Physical Therapy Center and will train for one session at their home or chosen location with the aid of a video guide.
Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxins increase the permeability of bacterial cell membrane leading to death of the cell. All gram positive bacteria, fungi, and gram-negative cocci are resistant to polymyxin B.

Appropriate methods should be used when performing in vitro susceptibility testing of polymyxin B1,2,3 The following in vitro susceptibility test criteria should only be used for interpreting the results of polymyxin B susceptibility testing against P.aeruginosa when the indicated quality control parameters are met during testing.  
  
In Vitro Susceptibility Test Interpretive Criteria for Polymyxin B Sulfate Against Pseudomonas aeruginosa

In Vitro Susceptibility Test Quality Control Ranges for Polymyxin B Sulfate Against Pseudomonas aeruginosa

Polymyxin B sulfate is not absorbed from the normal alimentary tract. Since the drug loses 50 percent of its activity in the presence of serum, active blood levels are low. Repeated injections may give a cumulative effect. Levels tend to be higher in infants and children. The drug is excreted slowly by the kidneys. Tissue diffusion is poor and the drug does not pass the blood brain barrier into the cerebrospinal fluid. In therapeutic dosage, polymyxin B sulfate causes some nephrotoxicity with tubule damage to a slight degree.
The study is a single-center, prospective, open-label cohort study designed to determine the efficacy of liver perfusion of marginal ECD livers on a perfusion machine before liver transplantation. Donor livers will be preserved with standard cooling followed by three perfusion modes (Dual hypothermic oxygenated machine perfusion (DHOPE) / Controlled oxygenated rewarming (COR) / Normothermic machine perfusion (NMP)), a method used internationally to pre-treating marginal livers before liver transplantation and which able testing of function and quality before a transplantation is performed. Only livers that fulfill international criteria (Groningen criteria) will be approved for Ltx. In this study microdialysis will be used to monitoring the liver during machine perfusion and up to 14 days in the postoperative course to monitor the function of the liver. The hypothesis is that microdialysis will provide a better prediction of liver function than the existing Groeningen criteria. The investigators expect that most included patients, who receive ECD livers perfused on a machine, will receive a postoperative well-functioning liver graft which entails a significant survival benefit. The study is designed as a cohort study because included patients have a very poor prognosis (median overall survival of approx. 6 months) and others treatment options are lacking. The primary objective is to establish definitive, objective criteria for pre-transplant liver function by defining a threshold value for microdialysis parameters (especially lactate) between donor livers that will restore function and those that will not during ex vivo machine perfusion in ECD livers, which are superior to established criteria (Groeningen and Viability testing and transplantation of marginal livers (VITTAL) criteria)). The primary endpoint is microdialysis lactate level between donor livers after 4 hours of normothermic machine perfusion in ECD livers.

The follow-up period is 12 months.
A pharmaceutical composition for preventing and treating neurodegenerative diseases is provided to prevent apoptosis of neuroblastoma cells and have anti-inflammatory activity. A pharmaceutical composition for treating neurodegenerative diseases comprises a polyphenolic compounds having anti-inflammatory activity or nerve protection effect. The polyphenolic compound comprises 3-methylcatechol, 4-methylcatechol, 4-tert-butylcatechol, and catechol. The anti-inflammatory activity of the pharmaceutical composition is to suppressing nitric oxide (NO) and TNF-alpha. The anti-inflammatory activity of the pharmaceutical composition is to inhibit the phosphorylation of P-38 MAPK (Mitogen-activated protein kinase). The neurodegenerative diseases are Alzheimer's diseases, Parkinson's diseases, and HIV dementia (human immunodeficiency virus-associated dementia).
The study participants will be enrolled in a visit to a group of psychologic therapy women cancer survivors who met monthly and who have submitted to breast cancer treatment in a hospital in the city of Maceió (AL), Brazil, classified as High Complexity Oncologic Clinic. At this visit, the proposal for physical exercises will be presented in the hospital area. Volunteers will be scheduled for an in-person visit and assessed for eligibility. Those who meet all the inclusion/exclusion criteria will be invited to integrate the physical exercise intervention.

The 12-week exercise intervention will consist of a combined exercise including an aerobic component (dance) and resistance training, and aerobic exercise (i.e., walking). Participants will be evaluated pre- and post-intervention in terms of several health indicators. All ethical approvals were collected before study initiation.
FIELD: shaving devices and methods. SUBSTANCE: system for wet shaving includes blade member; part touching skin near blade member and having (before first use of shaving system) rigid polymeric composite used for shaving. Composite includes first portion open in lengthwise direction and having first member for shaving and adjacent to first portion second portion open in lengthwise direction and having second member for shaving. Composition of first open portion differs from that of second open portion. EFFECT: improved design providing comfortable shaving due to lowered friction braking (at side of skin) of force necessary for cutting hairs, reduced skin irritation. 19 cl, 5 dwg _
Intravenous heparin is considered standard therapy to prevent clotting complications in patients on ECMO, however the optimal method of heparin dosing has not yet been determined. International surveys have shown that most ECMO centers use adjusted dose heparin to achieve an activated clotting time of at least 180 seconds. However, heparin may contribute to the most common complication of ECMO - bleeding. Advances in material technology have potentially reduced the thrombogenicity of modern ECMO circuits. Our observational data suggest that fixed low dose heparin infusion may reduce the rate of bleeding complications from 75% to 50% compared to standard adjusted-dose heparin, without increasing clotting complications. We intend to perform a randomized controlled trial in adults receiving venovenous ECMO comparing these two heparin regimens. The main outcome measures are bleeding complications and oxygenator failure due to clotting. A safety committee will monitor the results of the study. Power calculations indicate a sample size of 110 patients is required, which we estimate will take us five years to achieve.